aldosterone antagonists

Summary

Summary: Compounds which inhibit or antagonize the biosynthesis or actions of aldosterone.

Top Publications

  1. ncbi Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
    Bertram Pitt
    University of Michigan, Ann Arbor, USA
    N Engl J Med 348:1309-21. 2003
  2. ncbi Review of aldosterone- and angiotensin II-induced target organ damage and prevention
    Allan D Struthers
    Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, Tayside DD1 9SY, Dundee, UK
    Cardiovasc Res 61:663-70. 2004
  3. pmc Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity
    Jane A Leopold
    Whitaker Cardiovascular Institute, 700 Albany Street, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Nat Med 13:189-97. 2007
  4. ncbi Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis
    Puneeta Tandon
    Hospital Clinic, Liver Unit, Barcelona, Spain
    J Hepatol 53:273-82. 2010
  5. ncbi Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17 beta-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol
    Ingrid J M Duijkers
    Dinox, Groningen, The Netherlands
    Eur J Contracept Reprod Health Care 15:314-25. 2010
  6. ncbi Eplerenone in patients with systolic heart failure and mild symptoms
    Faiez Zannad
    INSERM, Centre d Investigation Clinique 9501 and Unité 961, and the Department of Cardiology, Nancy University, Nancy, France
    N Engl J Med 364:11-21. 2011
  7. ncbi Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction
    Carmem Luíza Sartório
    Medizinische Klinik und Poliklinik I, Universitatsklinikum Wurzburg, Bayerische Julius Maximilians Universität Würzburg, Germany
    Hypertension 50:919-25. 2007
  8. pmc Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion
    Massimiliano Caprio
    Department of Medicine Division of Cardiology, Tufts Medical Center and Tufts University School of Medicine, Boston, MA 02111, USA
    Circ Res 102:1359-67. 2008
  9. ncbi Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1
    Shigeru Shibata
    Department of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Hypertension 49:355-64. 2007
  10. ncbi Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo
    N J Brown
    Departments of Medicine and Pharmacology, Pathology, and Radiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Kidney Int 58:1219-27. 2000

Detail Information

Publications233 found, 100 shown here

  1. ncbi Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
    Bertram Pitt
    University of Michigan, Ann Arbor, USA
    N Engl J Med 348:1309-21. 2003
    ....
  2. ncbi Review of aldosterone- and angiotensin II-induced target organ damage and prevention
    Allan D Struthers
    Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, Tayside DD1 9SY, Dundee, UK
    Cardiovasc Res 61:663-70. 2004
    ....
  3. pmc Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity
    Jane A Leopold
    Whitaker Cardiovascular Institute, 700 Albany Street, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Nat Med 13:189-97. 2007
    ..These findings demonstrate that aldosterone induces a G6PD-deficient phenotype to impair endothelial function; aldosterone antagonism or gene transfer of G6pd improves vascular reactivity by restoring G6PD activity...
  4. ncbi Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis
    Puneeta Tandon
    Hospital Clinic, Liver Unit, Barcelona, Spain
    J Hepatol 53:273-82. 2010
    Renin-angiotensin-aldosterone antagonists [ACE inhibitors (ACEi), angiotensin receptor blockers (ARB), aldosterone antagonists (AA)] are potential therapies for portal hypertension...
  5. ncbi Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17 beta-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol
    Ingrid J M Duijkers
    Dinox, Groningen, The Netherlands
    Eur J Contracept Reprod Health Care 15:314-25. 2010
    ..To compare the effects on ovarian activity of two oral contraceptives containing nomegestrol acetate (NOMAC)/17 beta-oestradiol (E2) or drospirenone (DRSP)/ethinylestradiol (EE)...
  6. ncbi Eplerenone in patients with systolic heart failure and mild symptoms
    Faiez Zannad
    INSERM, Centre d Investigation Clinique 9501 and Unité 961, and the Department of Cardiology, Nancy University, Nancy, France
    N Engl J Med 364:11-21. 2011
    ..We evaluated the effects of eplerenone in patients with chronic systolic heart failure and mild symptoms...
  7. ncbi Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction
    Carmem Luíza Sartório
    Medizinische Klinik und Poliklinik I, Universitatsklinikum Wurzburg, Bayerische Julius Maximilians Universität Würzburg, Germany
    Hypertension 50:919-25. 2007
    ..Underlying mechanisms involve inhibition of vascular angiotensin-converting enzyme upregulation and improvement of endothelial NO synthase-derived NO bioavailability...
  8. pmc Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion
    Massimiliano Caprio
    Department of Medicine Division of Cardiology, Tufts Medical Center and Tufts University School of Medicine, Boston, MA 02111, USA
    Circ Res 102:1359-67. 2008
    In clinical trials, aldosterone antagonists decrease cardiovascular mortality and ischemia by unknown mechanisms...
  9. ncbi Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1
    Shigeru Shibata
    Department of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Hypertension 49:355-64. 2007
    ..Aldosterone can directly modulate podocyte function, possibly through the induction of oxidative stress and Sgk1...
  10. ncbi Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo
    N J Brown
    Departments of Medicine and Pharmacology, Pathology, and Radiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Kidney Int 58:1219-27. 2000
    ....
  11. ncbi Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients
    Carmine Savoia
    Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Hypertension 51:432-9. 2008
    ....
  12. ncbi The evolution of aldosterone antagonists
    Susan M Garthwaite
    Pfizer Incorporated, Global Project Management, Skokie, IL, USA
    Mol Cell Endocrinol 217:27-31. 2004
    ..its release, what is its role in the pathophysiology of cardiovascular disease, how to make and study aldosterone antagonists, and for what medical purposes these agents are useful...
  13. ncbi Use of aldosterone antagonists in heart failure
    Nancy M Albert
    Nursing Institute and Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, Ohio, USA
    JAMA 302:1658-65. 2009
    b>Aldosterone antagonists are recommended for patients with moderate to severe heart failure (HF) and systolic dysfunction...
  14. ncbi Mineralocorticoid action and sodium-hydrogen exchange: studies in experimental cardiac fibrosis
    Morag Young
    Endocrine Genetics, Prince Henry s Institute of Medical Research, Clayton, Victoria 3168, Australia
    Endocrinology 144:3848-51. 2003
    ....
  15. ncbi Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines
    Biykem Bozkurt
    Winters Center for Heart Failure Research, VA Medical Center, Baylor College of Medicine, Houston, Texas, USA
    J Am Coll Cardiol 41:211-4. 2003
    ..This study was designed to investigate the appropriateness and complications of the use of spironolactone for heart failure (HF) in clinical practice...
  16. ncbi Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials
    Justin A Ezekowitz
    Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada
    Eur Heart J 30:469-77. 2009
    ..Aldosterone blockade has been used to treat acute myocardial infarction (MI) and chronic heart failure...
  17. ncbi Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline
    John W Funder
    Prince Henry s Institute of Medical Research, Clayton, Vic, Australia
    J Clin Endocrinol Metab 93:3266-81. 2008
    ..Our objective was to develop clinical practice guidelines for the diagnosis and treatment of patients with primary aldosteronism...
  18. ncbi Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction
    James E Udelson
    Tufts Medical Center, 750 Washington Street, Boston, MA 02111, USA
    Circ Heart Fail 3:347-53. 2010
    ..Few data are available on effects of aldosterone antagonism in patients with mild-to-moderate HF...
  19. ncbi Long-term renal outcomes in patients with primary aldosteronism
    Leonardo A Sechi
    Hypertension Unit, Division of Internal Medicine, Department of Experimental and Clinical Pathology and Medicine, University of Udine, Udine, Italy
    JAMA 295:2638-45. 2006
    ..Experimental animal studies indicate that exposure to increased aldosterone levels might result in renal damage, but the clinical evidence supporting this role of aldosterone is preliminary...
  20. ncbi Low-dose spironolactone in the management of resistant hypertension: a surveillance study
    Deirdre A Lane
    University Department of Medicine, City Hospital, Birmingham, UK
    J Hypertens 25:891-4. 2007
    ..This drug was recommended in 133 patients who were already receiving an angiotensin-blocking drug in addition to other therapies...
  21. ncbi Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II
    Anastasia Chrysostomou
    Department of Nephrology, Royal Melbourne Hospital, Parkville, Victoria 3052, Australia
    Clin J Am Soc Nephrol 1:256-62. 2006
    ..Results suggest no advantage of triple blockade over dual blockade of the renin-angiotensin-aldosterone system to reduce proteinuria...
  22. ncbi Aldosterone antagonist improves diastolic function in essential hypertension
    Anna M Grandi
    Department of Clinical and Biological Sciences, University of Insubria, Varese, Italy
    Hypertension 40:647-52. 2002
    ..This improvement, not accounted for by changes in blood pressure and left ventricular mass, can be therefore ascribed to a direct action of the drug on the myocardium...
  23. ncbi Induction of cardiac fibrosis by aldosterone
    P Lijnen
    Department of Molecular and Cardiovascular Research, Faculty of Medicine, University of Leuven, Belgium
    J Mol Cell Cardiol 32:865-79. 2000
    ....
  24. ncbi Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition
    Christian Otte
    Department of Psychiatry and Psychotherapy, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Neuropsychopharmacology 32:232-8. 2007
    ..The domains of cognitive function that are impaired after blockade of MR in men, that is, selective attention, visuospatial memory, and mental flexibility/set shifting appear to be remarkably similar to those described in animal studies...
  25. ncbi Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease
    Atsuhisa Sato
    Department of Internal Medicine, Mito Red Cross Hospital, Ibaraki, Japan
    Am J Hypertens 18:44-9. 2005
    ..Additional, larger, prospective, randomized double-blind studies will be needed for general acceptance of this strategy...
  26. ncbi Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet
    Tsutomu Wada
    Department of Clinical Pharmacology, University of Toyama, Toyama 930 0194, Japan
    Endocrinology 151:2040-9. 2010
    ..These results indicate that inhibition of mineralocorticoid receptor might be a beneficial therapeutic approach for diet-induced phenotypes of metabolic syndrome and fatty liver...
  27. ncbi Aldosterone antagonists in congestive heart failure
    Judith Soberman
    Division of Cardiovascular Diseases, University of Tennessee Health Science Center, Dobbs Research Institute, Memphis 38163, USA
    Curr Opin Investig Drugs 3:1024-8. 2002
    ..system (RAAS) in the progression of CHF, and increased interest in the use of aldosterone antagonists. While ACE inhibitors have had the largest impact on adverse events in CHF, numerous studies have shown ..
  28. ncbi Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study
    Hideo Izawa
    Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya 466 8550, Japan
    Circulation 112:2940-5. 2005
    ....
  29. ncbi Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes
    Murray Epstein
    University of Miami School of Medicine, Miami, Florida, USA
    Clin J Am Soc Nephrol 1:940-51. 2006
    ..Co-administration of EPL50 or EPL100 with an ACE inhibitor as compared with an ACE inhibitor alone significantly reduces albuminuria in patients with diabetes without producing significant increases in hyperkalemia...
  30. ncbi Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients
    R J MacFadyen
    Department of Clinical Pharmacology, University of Dundee, Ninewells Hospital and Medical School, UK
    Cardiovasc Res 35:30-4. 1997
    ..Experimental data suggest that aldosterone has harmful effects promoting myocardial fibrosis and disturbing autonomic balance. There has been no evidence of these potential effects in intact man...
  31. pmc Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension
    James R Sowers
    University of Missouri, Columbia, Missouri, USA
    Ann Intern Med 150:776-83. 2009
    ....
  32. ncbi Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction
    Howard Trachtman
    Department of Pediatrics, Schneider Children s Hospital, New Hyde Park, New York 11040, USA
    J Urol 172:1590-4. 2004
    ..We conducted experiments to determine whether administration of spironolactone, a mineralocorticoid receptor antagonist, reduced renal fibrosis in an experimental model of obstructive uropathy...
  33. ncbi Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee
    Javed Butler
    Department of Medicine, Division of Cardiology, Emory University, Atlanta, GA, USA
    J Card Fail 18:265-81. 2012
    b>Aldosterone antagonists (or mineralocorticoid receptor antagonists [MRAs]) are guideline-recommended therapy for patients with moderate to severe heart failure (HF) symptoms and reduced left ventricular ejection fraction (LVEF), and in ..
  34. ncbi Mineralocorticoid receptor antagonist spironolactone prevents pig serum-induced hepatic fibrosis in rats
    Genro Fujisawa
    Divisions of Endocrinology and Metabolism and Nephrology, Department of Internal Medicine, Jichi Medical School, Minamikawachi, Tochigi, Japan
    Transl Res 148:149-56. 2006
    ..The aldosterone produced in the injured liver contributes to the PS-induced hepatic fibrosis...
  35. ncbi Aldosterone target organ protection by eplerenone
    Amy E Rudolph
    Pharmacia Corporation, Cardiovascular and Metabolic Diseases, 800 N Lindbergh Blvd, T1G T108W, St Louis, MO 63167, USA
    Mol Cell Endocrinol 217:229-38. 2004
    ....
  36. ncbi Beneficial impact of spironolactone in diabetic nephropathy
    Katrine Jordan Schjoedt
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 68:2829-36. 2005
    ..We therefore aimed to evaluate the short-term effect of aldosterone antagonism with spironolactone on albuminuria and blood pressure in diabetic nephropathy...
  37. ncbi Role of central nervous system aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive rats
    Bing S Huang
    University of Ottawa Heart Institute, Ottawa, ON, Canada K1Y 4W7
    Am J Physiol Regul Integr Comp Physiol 296:R994-R1000. 2009
    ..These results suggest that, in Dahl S rats, high salt intake increases aldosterone synthesis in the hypothalamus and aldosterone acts as the main MR agonist activating central pathways contributing to salt-induced hypertension...
  38. ncbi Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results
    Alessandro Boccanelli
    Department of Cardiovascular Diseases, San Giovanni Addolorata Hospital, Roma, Italy
    Eur J Heart Fail 11:68-76. 2009
    ..Aldosterone receptor antagonists improve outcome in severe HF, but no information is available in NYHA class II...
  39. ncbi Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study
    Jürgen Dinger
    Director, ZEG Berlin Center for Epidemiology and Health Research, Invalidenstrasse 115, 10115 Berlin, Germany
    J Fam Plann Reprod Health Care 36:123-9. 2010
    ..The secondary objective was to investigate the VTE risk associated with drospirenone/ethinylestradiol (DRSP/EE) in comparison to low-dose LNG/EE...
  40. ncbi Long-term effect of spironolactone on cardiac structure as assessed by analysis of ultrasonic radio-frequency signals in patients with ventricular hypertrophy
    Nagahiro Nishikawa
    Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita 565 0871, Japan
    Circ J 69:1394-400. 2005
    ....
  41. ncbi Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF)
    Faiez Zannad
    INSERM, Centre d Investigation Cliniques CIC 9501 and U961, CHU and Department of Cardiology, Nancy University, Nancy, France
    Eur J Heart Fail 12:617-22. 2010
    In chronic heart failure (HF), aldosterone antagonists have been shown to improve survival in patients with low ejection fraction and moderate-to-severe symptoms [New York Heart Association (NYHA) classes III and IV]...
  42. ncbi Spironolactone improves diastolic function in the elderly
    Chanwit Roongsritong
    Division of Cardiology, Texas Tech University Health Sciences Center, Lubbock, TX 79430 9410, USA
    Clin Cardiol 28:484-7. 2005
    ..Increased myocardial fibrosis, a major determinant of diastolic function, has been observed with advancing age. Spironolactone prevents age-related increases in myocardial fibrosis in old normotensive rats...
  43. ncbi Safety of spironolactone use in ambulatory heart failure patients
    Ricardo J Lopes
    Department of Cardiology, Hospital São João 4200 319 Porto, Portugal
    Clin Cardiol 31:509-13. 2008
    ..There is limited information on the use, side effects, and withdrawal rate of spironolactone in routine clinical practice...
  44. ncbi Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease
    Richard A Preston
    Division of Clinical Pharmacology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
    Hypertension 53:754-60. 2009
    ....
  45. ncbi Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure
    Larisa H Cavallari
    Department of Pharmacy Practice, University of Illinois at Chicago, 60612 7230, USA
    Pharmacotherapy 30:1-9. 2010
    ..To identify patient-specific factors associated with spironolactone-induced potassium level elevation in patients with heart failure...
  46. ncbi Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology
    Jennifer L Wilkinson-Berka
    Department of Immunology, Monash University, Commercial Rd, Prahran, Victoria, Australia, 3004
    Circ Res 104:124-33. 2009
    ..We make the first report that MR and aldosterone influence retinal vasculopathy, which may involve inflammatory and G6PD mechanisms. MR antagonism may be relevant when developing treatments for retinopathies that target the RAAS...
  47. pmc Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy
    Uzma F Mehdi
    University of Texas Southwestern Medical Center, 5939 Harry Hines Boulevard, Dallas, TX 75930, USA
    J Am Soc Nephrol 20:2641-50. 2009
    ..These results support the need to conduct a long-term, large-scale, renal failure outcomes trial...
  48. ncbi A comparison of the aldosterone-blocking agents eplerenone and spironolactone
    Allan Struthers
    Division of Medicine and Therapeutics, Ninewells Hospital and Medical School, Dundee, UK
    Clin Cardiol 31:153-8. 2008
    ..Choice of a specific agent should be based on individual patient issues, such as the nature of heart failure and patient concerns about adverse events...
  49. ncbi Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone
    Paul Mulder
    Faculte de Medecine et Pharmacie, INSERM U644, 22 Boulevard Gambetta, 76183 Rouen Cedex, France
    Eur Heart J 29:2171-9. 2008
    ..Inhibition of aldosterone synthase, the key enzyme in aldosterone formation, could be an alternative strategy for mineralocorticoid-receptor antagonists in congestive heart failure (CHF), but its effect in CHF is unknown...
  50. ncbi Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study
    Stefano Bianchi
    Unità Operativa Nefrologica, Spedali Riuniti di Livorno, Livorno, Italy
    Am J Kidney Dis 46:45-51. 2005
    ..Hence, administration of aldosterone receptor antagonists may provide additional renal benefits to the ACE inhibitors and ARBs...
  51. pmc Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis
    Sankar D Navaneethan
    Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Clin J Am Soc Nephrol 4:542-51. 2009
    Addition of aldosterone antagonists (AA) might provide renal benefits to proteinuric chronic kidney disease (CKD) patients over and above the inhibition of renin-angiotensin system blockers (RAS)...
  52. ncbi The new biology of aldosterone
    John M C Connell
    MRC Blood Pressure Group, Division of Cardiovascular and Medical Sciences, University of Glasgow, Gardiner Institute, Western Infirmary, Glasgow G11 6NT, UK
    J Endocrinol 186:1-20. 2005
    ..These new findings highlight the role of aldosterone as a key cardiovascular hormone and extend our understanding of its role in determining adverse cardiovascular outcomes...
  53. ncbi Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study
    Bertram Pitt
    University of Michigan Health System, Ann Arbor, Mich, USA
    Circulation 108:1831-8. 2003
    ..This study compared LVH regression during treatment with the selective aldosterone blocker eplerenone, enalapril, and their combination in patients with hypertension...
  54. ncbi Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model
    Xiaoyan Zhou
    Hypertension Research Laboratories, Ochsner Clinic Foundation, New Orleans, LA, USA
    Am J Nephrol 24:242-9. 2004
    ....
  55. ncbi The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation
    Jürgen C Dinger
    Center for Epidemiology and Health Research ZEG, 10115 Berlin, Germany
    Contraception 75:344-54. 2007
    ..The study was conducted to compare risks of adverse cardiovascular and other events associated with the use of drospirenone (DRSP)-containing oral contraceptives (OCs) and other OCs...
  56. ncbi Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker
    Miki Nagase
    Department of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
    Hypertension 47:1084-93. 2006
    ....
  57. ncbi Spironolactone improves lung diffusion in chronic heart failure
    Piergiuseppe Agostoni
    Centro Cardiologico Monzino, IRCCS, Istituto di Cardiologia, Universita di Milano, Via Parea 4, 20138 Milan, Italy
    Eur Heart J 26:159-64. 2005
    ..Spironolactone improves clinical conditions and prognosis in chronic HF and reduces connective tissue matrix turnover; DLCO abnormalities in chronic HF are related to increase in fibrosis and connective tissue derangement...
  58. ncbi Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study
    David N Juurlink
    Department of Medicine University of Toronto, Toronto
    N Engl J Med 351:543-51. 2004
    ..Use of angiotensin-converting-enzyme (ACE) inhibitors is also indicated in these patients. However, life-threatening hyperkalemia can occur when these drugs are used together...
  59. ncbi Effects of eplerenone versus losartan in patients with low-renin hypertension
    Myron H Weinberger
    Hypertension Research Center, Indiana University School of Medicine, Indianapolis, IN 46202 5111, USA
    Am Heart J 150:426-33. 2005
    ..Agents that block aldosterone at its receptor sites, therefore, should have significant clinical benefit in patients with low-renin hypertension...
  60. ncbi Mineralocorticoid receptor antagonism in experimental atherosclerosis
    Sanjay Rajagopalan
    Department of Internal Medicine, University of Michigan, Ann Arbor, Mich, USA srajagop umich edu
    Circulation 105:2212-6. 2002
    ..We hypothesized that there is local expression of the mineralocorticoid receptor (MR) in the vasculature and that the use of a selective aldosterone receptor antagonist (SARA) improves endothelial function in early atherosclerosis...
  61. pmc Aldosterone-induced inflammation in the rat heart : role of oxidative stress
    Yao Sun
    Department of Medicine, Division of Cardiovascular Diseases, University of Tennessee Health Science Center, Memphis 38163, USA
    Am J Pathol 161:1773-81. 2002
    ..Spionolactone, PDTC, and NAC each attenuated these responses suggesting ALDO/salt induction of oxidative/nitrosative stress is responsible for the appearance of this proinflammatory phenotype...
  62. pmc Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt
    William B Lea
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Kidney Int 75:936-44. 2009
    ..Our study shows that mineralocorticoid receptor antagonism and aldosterone synthase inhibition similarly decrease hypertrophy and interstitial fibrosis of the kidney and heart caused by angiotensin II and high salt...
  63. ncbi Eplerenone: a selective aldosterone receptor antagonist (SARA)
    J A Delyani
    Pharmacia, 4901 Searle Parkway, Skokie, IL 60077, USA
    Cardiovasc Drug Rev 19:185-200. 2001
    ..These studies will extend our understanding of selective aldosterone receptor antagonism in the treatment of chronic cardiovascular disease...
  64. ncbi Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats
    Jun Du
    Department of Pharmacology, Kagawa University Medical School, Kagawa, Japan
    Am J Physiol Renal Physiol 297:F802-8. 2009
    ..The combination of eplerenone and amlodipine improved renal injury more effectively than either monotherapy in high salt-fed DS rats, presumably by achieving their own renoprotective effects...
  65. ncbi Spironolactone use and renal toxicity: population based longitudinal analysis
    Li Wei
    Medicines Monitoring Unit MEMO, Division of Medical Sciences, Ninewells Hospital and Medical School, Dundee DD1 9SY
    BMJ 340:c1768. 2010
    ..To determine the safety of spironolactone prescribing in the setting of the UK National Health Service...
  66. ncbi Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors
    Matthew R Weir
    Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, 22 South Greene Street, Room N3W143, Baltimore, MD 21201, USA
    Clin J Am Soc Nephrol 5:531-48. 2010
    ..Moreover, these patients are likely to derive benefit from RAAS inhibition. Rather than denying them an effective treatment, electrolyte levels should be closely monitored in these patients...
  67. ncbi Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats
    Genro Fujisawa
    Divisions of Endocrinology, Department of Internal Medicine, Jichi Medical School, Minamikawachi, Tochigi, Japan
    Kidney Int 66:1493-502. 2004
    ..The present study investigated whether and how mineralocorticoid receptor antagonist spironolactone ameliorates early renal injury in streptozotocin-induced diabetic rats...
  68. ncbi Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications
    M Epstein
    Department of Medicine, University of Miami School of Medicine, Miami, FL, USA
    Am J Kidney Dis 37:677-88. 2001
    ..This is a US government work. There are no restrictions on its use...
  69. ncbi Cardiac aldosterone production in genetically hypertensive rats
    Y Takeda
    Second Department of Internal Medicine, Department of Health Sciences, School of Medicine, Kanazawa University, Kanazawa, Japan
    Hypertension 36:495-500. 2000
    ..These results suggest that the rat heart produces aldosterone and that endogenous cardiac aldosterone may affect cardiac function and hypertrophy in hypertension in rats...
  70. ncbi Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity
    Iris Feria
    Molecular Physiology Unit, Instituto de Investigaciones Biomedicas, UNAM, Mexico City, Mexico
    Kidney Int 63:43-52. 2003
    ....
  71. ncbi Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)
    Bertram Pitt
    University of Michigan Medical Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109, USA
    Circulation 118:1643-50. 2008
    ..This subanalysis examined the relationship between eplerenone, serum potassium (K(+)), and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)...
  72. ncbi Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response
    Daniela Fraccarollo
    Medizinische Klinik und Poliklinik I, Julius Maximilians Universitat Wurzburg, Wurzburg, Germany
    Hypertension 51:905-14. 2008
    ....
  73. ncbi Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker
    Yoshiyuki Furumatsu
    Department of Kidney Disease and Hypertension, Osaka General Medical Center, Japan
    Hypertens Res 31:59-67. 2008
    ..In conclusion, triple blockade of the RAAS was effective for the treatment of proteinuria in patients with non-diabetic nephropathy whose increased urinary protein had not responded sufficiently to a dual blockade...
  74. ncbi Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship
    F Zannad
    Centre d'Investigation Clinique INSERM-CHU, Centre Hospitalier Universitaire, Equipe d'Accueil EA 2403, , Nancy, France
    Hypertension 38:1227-32. 2001
    ....
  75. ncbi Effect of spironolactone on blood pressure in subjects with resistant hypertension
    Neil Chapman
    International Centre for Circulatory Health, Imperial College London, 59 North Wharf Rd, London W2 1PG, United Kingdom
    Hypertension 49:839-45. 2007
    ..Although nonrandomized and not placebo controlled, these data support the use of spironolactone in uncontrolled hypertension...
  76. ncbi Rapid non-genomic vasoconstrictor actions of aldosterone in the renal microcirculation
    Shuji Arima
    Department of Vascular and Geriatric Medicine, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama 589 8511, Japan
    J Steroid Biochem Mol Biol 102:170-4. 2006
    ..Thus, in addition to genomic actions, such non-genomic vasoconstrictor actions in the renal microcirculation may contribute to the deleterious renal effects of aldosterone in renal diseases...
  77. ncbi Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome
    Robert W Schrier
    Department of Medicine, University of Colorado Denver, Division of Renal Diseases and Hypertension, Aurora, CO 80045, USA
    Clin J Am Soc Nephrol 5:1132-40. 2010
    ..The effect of aldosterone in metabolic syndrome is also discussed in this review...
  78. ncbi Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial
    Leszek Tylicki
    Department of Nephrology Transplantology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland
    Am J Kidney Dis 52:486-93. 2008
    ....
  79. ncbi Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes
    E Harada
    Department of Cardiovascular Medicine, Kumamoto University School of Medicine, Japan
    Circulation 104:137-9. 2001
    ..Thus, spironolactone may suppress the progression of heart failure by blocking the effects of aldosterone and angiotensin II...
  80. ncbi Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism
    Rosana Poggio
    Heart Failure and Heart Transplant Program, Department of Cardiology, FLENI, Buenos Aires, Argentina
    Postgrad Med J 86:136-42. 2010
    ..of angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and aldosterone antagonists. High potassium concentrations in heart failure could lead to life threatening events, and therefore ..
  81. ncbi Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage
    Anette Fiebeler
    Medical Faculty of the Charite, HELIOS Klinikum Berlin, Franz Volhard Clinic, Berlin, Germany
    Circulation 111:3087-94. 2005
    ..We tested the hypothesis that reducing aldosterone by inhibiting CYP11B2 or by adrenalectomy (ADX) may ameliorate organ damage. Furthermore, we investigated how much local cardiac aldosterone originates from the adrenal gland...
  82. ncbi Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability
    Toshio Imanishi
    Department of Cardiovascular Medicine, Wakayama Medical University, 811 1, Kimiidera, Wakayama City, Wakayama 641 8510, Japan
    Hypertension 51:734-41. 2008
    ..Combined treatment with a selective aldosterone antagonist and an angiotensin-converting enzyme inhibitor has additive protective effects on endothelial function and on atherosclerotic changes via decreased nitrosative stress...
  83. ncbi Eplerenone: cardiovascular protection
    Nancy J Brown
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn 37232 6602, USA
    Circulation 107:2512-8. 2003
    ..This review provides an overview of the pharmacology, efficacy, and safety of a new, more selective aldosterone receptor antagonist, eplerenone, in the context of emerging concepts of the role of aldosterone in cardiovascular toxicity...
  84. ncbi Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism
    Asterios Karagiannis
    Aristotle University of Thessaloniki, Second Propedeutic Department of Internal Medicine, Medical School, Hippokration Hospital, Thessaloniki, Greece
    Expert Opin Pharmacother 9:509-15. 2008
    ..It was concluded that eplerenone was as effective as spironolactone in reducing BP in patients with IHA. The risk of mild hyperkalaemia was similar with both drugs...
  85. ncbi High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction
    Farzin Beygui
    Cardiology Department and INSERM U 856, Pitie Salpetriere University Hospital, Paris, France
    Circulation 114:2604-10. 2006
    ..Whether aldosterone level at presentation for STEMI is associated with adverse outcome remains unknown...
  86. ncbi A review of the medical treatment of primary aldosteronism
    P O Lim
    Department of Cardiology, Wales Heart Research Institute, University of Wales College of Medicine, Cardiff
    J Hypertens 19:353-61. 2001
    ..There is thus a timely need to review the literature for effective drug therapies and to speculate on other therapeutic options by taking into account recent advances in understanding of the PA disease pathophysiological process...
  87. ncbi How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?
    Morten Svensson
    Frederiksberg University Hospital, Department of Cardiology and Endocrinology Frederiksberg Copenhagen, Denmark
    J Card Fail 10:297-303. 2004
    ....
  88. ncbi Aldosterone antagonists in the treatment of heart failure
    Todd R Marcy
    University of Oklahoma College of Pharmacy, Oklahoma City, OK 73190, USA
    Am J Health Syst Pharm 63:49-58. 2006
    The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart failure are reviewed.
  89. ncbi Spironolactone improves angiotensin-induced vascular changes and oxidative stress
    Agostino Virdis
    Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montreal, Quebec, Canada
    Hypertension 40:504-10. 2002
    ..Our findings suggest that aldosterone may mediate some of angiotensin II-induced vascular effects in hypertension, in part via increased oxidative stress...
  90. ncbi Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension
    Myron H Weinberger
    Indiana University School of Medicine, Hypertension Research Center, Indianapolis 46202 5111, USA
    Am J Hypertens 15:709-16. 2002
    ..Eplerenone, a selective aldosterone blocker (SAB) that is highly specific for the aldosterone receptor, has the potential to be efficacious in the treatment of hypertension...
  91. ncbi Pharmacology of different progestogens: the special case of drospirenone
    R Sitruk-Ware
    Rockefeller University and Population Council, New York, NY 10021, USA
    Climacteric 8:4-12. 2005
    ..Drospirenone is also available in combination with estradiol as an HRT preparation (1 mg 17beta-estradiol/2 mg drospirenone; Angeliq, Schering AG)...
  92. ncbi Rationale for the use of aldosterone antagonists in congestive heart failure
    Ricardo Rocha
    Division of Cardiovascular and Metabolic Diseases, Pharmacia Corp, Skokie, Illinois, USA
    Drugs 62:723-31. 2002
    ..These findings suggest the dissociation between cardiovascular lesions and high blood pressure, and highlight the importance of aldosterone in the pathological changes...
  93. pmc Mineralocorticoid receptor antagonists and endothelial function
    Bradley A Maron
    Harvard Medical School, Brigham and Women s Hospital, Department of Medicine, Cardiovascular Division, 77 Avenue Louis Pasteur, NRB 0630K, Boston, MA 02115, USA
    Curr Opin Investig Drugs 9:963-9. 2008
    ..Therefore, the development of newer agents with more favorable side-effect profiles is needed...
  94. ncbi Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001
    Frederick A Masoudi
    Division of Cardiology, Department of Medicine, Denver Health Medical Center, Denver, CO 80204, USA
    Circulation 112:39-47. 2005
    ..We studied the adoption of spironolactone therapy after publication of the Randomized Aldactone Evaluation Study (RALES) in national cohorts of older patients hospitalized for heart failure...
  95. ncbi Drospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptoms
    O Ylikorkala
    Climacteric 8:1-3. 2005
  96. ncbi Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension
    William B White
    Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
    Circulation 112:1979-84. 2005
    ..In prior studies with DRSP in postmenopausal women that were focused on relief of menopausal symptoms, DRSP/E2 yielded significant reductions in blood pressure (BP)...
  97. ncbi Drospirenone and its antialdosterone properties
    A R Genazzani
    Department of Obstetrics and Gynecology, University of Pisa, Pisa, Italy
    Climacteric 10:11-8. 2007
    ..The combined actions of drospirenone on sodium and water retention and cardiovascular parameters make it a more attractive therapeutic option as a component of hormone replacement therapy than other synthetic progestins...
  98. ncbi Mechanisms of disease: local renin-angiotensin-aldosterone systems and the pathogenesis and treatment of cardiovascular disease
    Richard N Re
    Research Division, Ochsner Clinic Foundation, New Orleans, LA 70121, USA
    Nat Clin Pract Cardiovasc Med 1:42-7. 2004
    ....
  99. ncbi Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study
    B S Lee
    Department of Obstetrics and Gynecology, College of Medicine, Yonsei University, Seoul, Republic of Korea
    Maturitas 57:361-9. 2007
    ....
  100. ncbi Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial
    David F Archer
    CONRAD Clinical Research Center, 601 Colley Avenue, Norfolk, VA 23507, USA
    Menopause 12:716-27. 2005
    ....
  101. ncbi Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinas
    Shigefumi Nakano
    Department of Hypertension and Cardiorenal Medicine, Dokkyo University School of Medicine, Shimotsuga gun, Tochigi 321 0293, Japan
    Hypertens Res 28:925-36. 2005
    ..Spironolactone may be useful as a cardioprotective agent to prevent cardiovascular remodeling via the ACE/EGFR/ERK, NAD(P)H oxidase/LOX-1, and Rho-kinase pathways...

Research Grants66

  1. Aldosterone, Autophagy, and Arterial Stiffness
    Jane A Leopold; Fiscal Year: 2013
    ..arterial stiffness by activating autophagy leading to VSMC phenotype transition and suggest further that aldosterone antagonists, interventions to increase G6PD activity, or autophagy modulators may have therapeutic benefit in ..
  2. Mineralocorticoid Antagonism and Endothelial Dysfunction
    BERENICE YOLANDE GITOMER; Fiscal Year: 2013
    ..Of note, aldosterone antagonists have been shown to improve endothelial dysfunction in a number of studies in other patient populations...
  3. Impact of Comorbidity Dyads on Heart Failure Treatment in Older Persons
    Jerry H Gurwitz; Fiscal Year: 2013
    ..3) to assess the clinical effectiveness and safety associated with the use of ACE inhibitors/angiotensin II receptor blockers (ARBs) and aldosterone antagonists for patients in the HF-chronic kidney disease dyad group.
  4. Genetic determinants of aldosterone escape in heart failure
    Larisa Cavallari; Fiscal Year: 2009
    ..goal of this line of investigation is to determine whether genotype is predictive of response to aldosterone antagonists in heart failure...
  5. ACTION - A CHF Trial Investigating Outcomes of Exercise
    Gregg Fonarow; Fiscal Year: 2006
    ..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..
  6. HEART FAILURE & NORMAL SYSTOLIC FUNCTION IN OLDER ADULTS
    Frederick Masoudi; Fiscal Year: 2004
    ..abstract_text> ..
  7. Diabetes and Drug-Associated Hyperkalemia: Effect of Laboratory Monitoring
    Marsha Raebel; Fiscal Year: 2008
    ..The findings will also assist in developing a framework for future studies to evaluate the effects and costs of medication-laboratory monitoring among patients with diabetes. [unreadable] [unreadable] [unreadable] [unreadable]..
  8. PREVENTION OF STROKE DYSFUNCTION BY ACE INHIBITION
    CHARLES STIER; Fiscal Year: 2003
    ..abstract_text> ..
  9. PAI-1 and The Vascular Toxicity of Aldosterone
    Nancy Brown; Fiscal Year: 2005
    ..This multi-disciplinary approach will generate new information regarding the role of aldosterone in vascular toxicity and, thus, improve our ability to prevent and treat cardiovascular disease. ..
  10. Vanderbilt Mentored Clinical Research Scholar Program
    Nancy Brown; Fiscal Year: 2006
    ..The VCRS program will train successful new clinical investigators who will serve as leaders role in the post-genomic era. [unreadable] [unreadable] [unreadable]..
  11. RAAS, Inflammation & Post-Operative Atrial Fibrillation
    Nancy Brown; Fiscal Year: 2009
    ..abstract_text> ..
  12. Lipoproteins, HIV, and Antiretroviral Therapy in SMART
    Daniel Duprez; Fiscal Year: 2008
    ..This proposal will produce additional information that will enhance their disease-free survival rate. (End of Abstract) [unreadable] [unreadable] [unreadable]..
  13. TRAINING CURRICULUM IN PATIENT ORIENTED RESEARCH
    Robert Toto; Fiscal Year: 2004
    ..The proposed program will provide young physicians and scientists with the skills needed to conduct clinical investigations and to compete for federal and non-federal research funding. ..
  14. DOXYCYCLINE FOR BLEEDING IN PROGESTIN ONLY CONTRACEPTORS
    David Archer; Fiscal Year: 2006
    ..If successful, DOX treatment could become an important adjuvant for treatment of this and possibly other inflammatory disorders effecting reproductive tract tissues. ..
  15. ACTION - A CHF Trial Investigating Outcomes of Exercise
    CHRISTOPHER O CONNOR; Fiscal Year: 2008
    ..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..
  16. Improving Outcomes in Diabetic Nephropathy
    Robert Toto; Fiscal Year: 2008
    ..PERFORMANCE SITE ========================================Section End=========================================== ..
  17. African American Study of Kidney Disease and Hypertensi*
    Robert Toto; Fiscal Year: 2007
    ..Such results might eventually lead to new strategies that delay or prevent ESRD. ..
  18. Pregnane X Receptor: Regulation and Pharmacogenomics
    Erin Schuetz; Fiscal Year: 2007
    ..In total this proposal describes a comprehensive set of experiments to determine how PXR is regulated. ..
  19. International Network and Registry for TMA
    Howard Trachtman; Fiscal Year: 2007
    ..These include essential hypertension, diabetes, hyperlipidemia, myocardial infarction, and chronic kidney disease. [unreadable] [unreadable]..
  20. Selective Modulation of Thyroid Receptor Action
    John Baxter; Fiscal Year: 2007
    ..This study will expand our understanding of selective TR modulation in specific and NR action in general. ..
  21. Michigan Mentored Clinical Scholars Program
    David Schteingart; Fiscal Year: 2007
    ..On the basis of these resources, we are confident we can offer an outstanding pro_am for the training of clinical research scholars. ..
  22. Urinary Biomarkers for Acute Kidney Injury in Critical Illness
    Steven Coca; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  23. Aldosterone, Histone Demethylase and Cardiovascular Disease
    Gordon H Williams; Fiscal Year: 2010
    ..This project is designed to assess one of those mechanisms thereby providing entrie to developing more directed therapy to treat cardiovascular diseases. ..
  24. Non-Modulation Phenotype and Vascular Dysfunction in Diabetes Mellitus
    Gordon H Williams; Fiscal Year: 2010
    ....
  25. Low-Renin Hypertension in African Americans
    John Pratt; Fiscal Year: 2003
    ..In summary, we explore unique but simple approaches to treatment of low-renin hypertension in blacks, a treatment modality that could prove useful to many patients currently with uncontrolled blood pressure. ..
  26. Partnership Program to Reduce Cardiovascular Disparities
    Elijah Saunders; Fiscal Year: 2008
    ..We strongly expect improved outcomes/awareness of cardiovascular health among minority patients serviced by both BSBHS and UMB. ..
  27. Biobehavioral Cardiovascular Health Promotion Intervention in a State Prison Syst
    Debra K Moser; Fiscal Year: 2010
    ..Effective management of cardiovascular risk factors could improve the health of inmates both while incarcerated and once released, and reduce the substantial personal and societal burden of cardiovascular disease. ..
  28. Heart Failure: Epidemiology & Outcomes in the Elderly
    Lesley Curtis; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  29. Cardiovascular and renal hemodynamics and the DASH diet
    Paul Conlin; Fiscal Year: 2009
    ..abstract_text> ..
  30. Inflammation & Prognosis in Decompensated Heart Failure
    GARY FELKER; Fiscal Year: 2008
    ..Felker's development into an established independent clinical investigator with expertise in both complex clinical research methodology and the role of inflammation in the pathophysiology of heart failure. ..
  31. Transforming PCI Informed Consent into an Evidence-based Decision-making Tool
    John A Spertus; Fiscal Year: 2010
    ..We will then estimate the cost-savings associated with more rational BAT use to test the hypothesis that PRISM will improve the cost-effectiveness of PCI. ..
  32. Drew AASK Cohort Study
    Keith Norris; Fiscal Year: 2007
    ..Such results might eventually lead to new strategies that delay or prevent ESRD. ..
  33. SCHOLARS IN CLINICAL SCIENCE PROGRAM
    Gordon Williams; Fiscal Year: 2004
    ..abstract_text> ..
  34. Oral Peptide Conjugate to Treat Congestive Heart Failure
    Kenneth James; Fiscal Year: 2003
    ..Phase II studies will involve pharmacokinetic and pharmacodynamic studies of the most promising candidates arising from Phase I studies. ..
  35. Role of IGF-1 In Diastolic Dysfunction of Aging
    Leanne Groban; Fiscal Year: 2003
    ..This study will provide the groundwork for future studies examining how IGF-1 signaling may modulate the programming and gene expression of the senescent myocardium. ..
  36. BRAIN AND CARDIAC ANGIOTENSIN II IN HYPERTENSION
    KATHLEEN BERECEK; Fiscal Year: 2003
    ..These studies are highly novel and could help to define new strategies not only for the treamtent of hypertension but its prevention as well. ..
  37. DST and Suicide Prediction
    Elizabeth Young; Fiscal Year: 2003
    ....
  38. Human monoclonal antibody therapy for HUS
    Howard Trachtman; Fiscal Year: 2004
    ..abstract_text> ..
  39. Digoxin Chiral Isolates as Improved Pharmaceuticals
    John Somberg; Fiscal Year: 2005
    ..The advantage would be a treatment for AF that did not cause cardiac augmentation and vasoconstriction or a treatment for CHF that does not cause heart rate slowing or conduction disturbances. ..
  40. VASCULAR DISEASE IN HBP--ANGII, PAI1, INSULIN AND GENES
    Gordon Williams; Fiscal Year: 2001
    ..With this information, specific preventive and therapeutic measures to retard the development of these complications could be proposed and tested in a clinical trial's format. ..
  41. HPA Axis in Depression and Anxiety
    Elizabeth Young; Fiscal Year: 2005
    ....
  42. Novel Therapies for Resistant FSGS
    Howard Trachtman; Fiscal Year: 2006
    ..The infrastructure that is established for the performance of this R21/R33 project should prove useful for the efficient assessment of additional novel therapies that will be developed in the future for patients with primary FSGS. ..
  43. ANGIOTENSIN, LEPTIN, AND THE SYMPATHETIC NERVOUS SYSTEM
    Lisa Cassis; Fiscal Year: 2001
    ....
  44. Mechanisms of Aldosterone Induced Cardiovascular Damage
    Gordon Williams; Fiscal Year: 2006
    ..Our results should better define the rationale for the use of mineralocorticoid receptor antagonists to prevent damage to the heart and other tissues when ALDO levels are inappropriate relative to Na intake. ..
  45. BIOLOGY OF COMORBID DEPRESSION AND ANXIETY
    Elizabeth Young; Fiscal Year: 2001
    ..The results of these studies will provide data on whether the biology of these disorders support the nosological distinction between panic disorder, pure major depression and major depression with co-morbid panic disorder. ..
  46. VOLTAGE GATED CARDIAC POTASSIUM CHANNELS
    Katherine Murray; Fiscal Year: 2001
    ....
  47. Neurohormonal Blockade and Outcomes in Diastolic Heart Failure
    Ali Ahmed; Fiscal Year: 2010
    ..angiotensin-converting enzyme inhibitors (or angiotensin receptor blockers), beta-blockers and aldosterone antagonists, in three propensity-matched populations of Organized Program to Initiate Life-Saving Treatment in ..
  48. Fusion Proteins As Probes of P450 Structure and Function
    Richard Auchus; Fiscal Year: 2004
    ..In addition, this approach might be generally applicable to structural studies of membrane-bound proteins. ..
  49. Molecular Modulation of Cardiac Na+ Channel Function
    Katherine Murray; Fiscal Year: 2004
    ..abstract_text> ..
  50. Oxidized Linoleic Acid, Aldosterone, and Obesity
    THEODORE GOODFRIEND; Fiscal Year: 2007
    ..abstract_text> ..
  51. Aldosterone in angiotensin II-induced hypertension
    Rudy Ortiz; Fiscal Year: 2005
    ..Unlike previous studies, the present study will provide a more comprehensive examination of the renal effects induced by aldo antagonism. ..
  52. MICROVASC OBSTRUCTION BY MRI AFTER CORONARY INTERVENTION
    Katherine Wu; Fiscal Year: 2004
    ..abstract_text> ..
  53. G6PD AND OXIDANT STRESS IN VASCULAR SMOOTH MUSCLE CELLS
    Jane Leopold; Fiscal Year: 2004
    ..abstract_text> ..
  54. Beta Cell Adaptation to Stress in Baboon Pancreas After Partial Pancreatectomy
    FRANCO BATTISTA FOLLI; Fiscal Year: 2010
    ....
  55. ATHEROGENESIS AND THE BONE MARROW ANGIOTENSIN SYSTEM
    Carlos Ferrario; Fiscal Year: 2004
    ..The proposed research will uncover novel mechanisms of atherogenesis that may have significant impact in the development of new therapeutic modalities applicable to cardiovascular and blood vessel diseases. ..
  56. Heart Failure and Beta-Blocker Use in Older Adults
    Ali Ahmed; Fiscal Year: 2006
    ..abstract_text> ..
  57. The Effect of Aldosterone on Cerebral Blood Vessels
    Anne Dorrance; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  58. Heart failure, chronic kidney disease, and renin-angiotensin system inhibition
    Ali Ahmed; Fiscal Year: 2009
    ....
  59. PHYSIOLOGY OF ESTROGEN'S MOOD EFFECT IN MENOPAUSAL WOMEN
    Hadine Joffe; Fiscal Year: 2007
    ..Such training will lay the foundation for a career of clinical investigation into the physiology of perimenopausal depression and the impact of hot flushes on sleep, mood, and quality-of-life. ..
  60. COLLABORATIVE R01-CARDIAC GRAFTS-FUNCTIONAL ANALYSES
    Robert Kloner; Fiscal Year: 2003
    ....
  61. Biologic Ventricular Assist Device
    Robert Kloner; Fiscal Year: 2004
    ..Identification and characterization of transplants will be carried out with PCR analysis of the Y chromosome (male cells into female host), detailed histologic analysis and immunostaining for muscle cell markers. ..
  62. Mesenchymal Stem Cells for Myocardial Infarction
    Robert Kloner; Fiscal Year: 2006
    ..abstract_text> ..